Editors’ Choice 2016 papers in Thrombosis and Haemostasis

References
1 De Caterina R, Husted S. Wallentin et al. Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2016; 115: 685-711.
2 Ageno W, Büller HR, Falanga A. et al. Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. Thromb Haemost 2016; 116: 1003-1010.
3 Weitz JI, Pollack Jr CV. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2015; 114: 1113-1126.
4 Hobl EL, Jilma B. Towards the al of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113: 931-942.
5 Squizzato A, Hunt BJ, Kinasewitz GT. et al. Supportive management strategies for disseminated intravascular coagulation. An international consensus. Thromb Haemost 2016; 115: 896-904.
6 Fauchier L, Poli D, Olshansky B. The SAMe-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anti-coagulation?. Thromb Haemost 2015; 114: 657-659.
7 Ruiz-Ortiz M, Bertomeu V, Cequier Á. et al. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost 2015; 114: 695-701.
8 Roldán V, Marín F. The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. Thromb Haemost 2015; 113: 671-673.
9 Sjögren V, Grzymala-Lubanski B, Renlund H. et al. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 2015; 113: 1370-1377.
10 Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016; 115: 31-39.
11 Raparelli V, Proietti M, Cangemi R. et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2016 116. Epub ahead of print
12 Chai-Adisaksopha C, Hillis C, Monreal M. et al. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis. Thromb Haemost 2015; 114: 819-825.
13 Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?. Thromb Haemost 2014; 111: 189-198.
14 Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113: 931-942.
15 Pollack Jr CV, Reilly PA, Bernstein R. et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015; 114: 198-205.
16 Glund S, Moschetti V, Norris S. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113: 943-951.
17 Honickel M, Treutler S, van Ryn J. et al. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost 2015; 113: 728-740.
18 Lowres N, Neubeck L, Salkeld G. et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014; 111: 1167-1176.
19 Paciaroni M, Agnelli G, Ageno W, Caso V. Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. Thromb Haemost 2016; 116: 410-416.
20 Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111: 789-797.
21 Pedersen A, Redfors P, Lundberg L. et al. Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic stroke. Thromb Haemost 2016; 116: 537-543.
22 Siegbahn A, Oldgren J, Andersson U. et al. D-dimer and factor VIIa in atrial fibrillation -prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY sub-study. Thromb Haemost 2016; 115: 921-930.
23 Philippart R, Brunet-Bernard A, Clementy N. et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost 2016; 115: 1056-1063.
24 Nielsen PB, Chao TF. The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb Haemost 2015; 113: 1170-1173.
25 Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?. Thromb Haemost 2015; 113: 1165-1169.
26 Lip GY, Skjøth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 2015; 114: 826-834.
27 Kittelson JM, Steg PG, Halperin JL. et al. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost 2016; 116: 544-553.
28 Husted S, de Caterina R, Andreotti F. et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014; 111: 781-782.
29 Lip GY, Keshishian A, Kamble S. et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation . Thromb Haemost 2016; 116: 975-986.
30 Hecker J, Marten S, Keller L. et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2016; 115: 939-949.
31 Freedman B, Lip GY. “Unreal world” or “real world” data in oral anticoagulant treatment of atrial fibrillation. Thromb Haemost 2016; 116: 587-589.
32 Beyer-Westendorf J, Ebertz F, Förster K. et al. N. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113: 1247-1257.
33 Seeger JD, Bykov K, Bartels DB. et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277-1289.
34 Villines TC, Schnee J, Fraeman K. et al. A comparison of the safety and effectiveness of dabigatran and warfarin in nonvalvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114: 1290-1298.
35 Avgil-Tsadok M, Jackevicius CA, Essebag V. et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost 2016; 115: 152-160.
36 Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world atrial fibrillation. Metaanalysis of observational comparison studies with vitamin K antagonists. Thromb Haemost 2016; 116: 754-763.
37 Balduini A, Di Buduo CA, Kaplan DL. Translational approaches to functional platelet production ex vivo. Thromb Haemost 2016; 115: 250-256.
38 Liu G, Liu G, Alzoubi K. et al. CD44 sensitivity of platelet activation, membrane scrambling and adhesion under high arterial shear rates. Thromb Haemost 2016; 115: 99-108.
39 Laffont B, Corduan A, Rousseau M. et al. Platelet microparticles reprogram macrophage gene expression and function. Thromb Haemost 2016; 115: 311-323.
40 Mao G, Jin J, Kunapuli SP, Rao AK. Nuclear factor-KB regulates expression of platelet phospholi-pase C-(32 (PLCB2). Thromb Haemost 2016; 116: 931-940.
41 Terrisse AD, Laurent PA, Garcia C. et al. The class I phosphoinositide 3-kinases a and (3 control anti-phospholipid antibodies-induced platelet activation. Thromb Haemost 2016; 115: 1138-1146.
42 Claesson K, Lindahl TL, Faxälv L. Counting the platelets: a robust and sensitive quantification method for thrombus formation. Thromb Haemost 2016; 115: 1178-1190.
43 Rutten B, Roest M, McClellan EA. et al. Platelet density per monocyte predicts adverse events in patients after percutaneous coronary intervention. Thromb Haemost 2016; 115: 353-360.
44 Eriksson O, Asplund A, Hegde G. et al. A stromal cell population in the large intestine identified by tissue factor expression that is lost during colorectal cancer progression. Thromb Haemost 2016; 116: 1050-1059.
45 Weber C, Shantsila E, Hristov M. et al. Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups “Atherosclerosis & Vascular Biology” and “Thrombosis”. Thromb Haemost 2016; 116: 626-637.
46 Santilli F, Marchisio M, Lanuti P. et al. Microparticles as new markers of cardiovascular risk in diabetes and beyond. Thromb Haemost 2016; 116: 220-234.
47 Shalhoub J, Viiri LE, Cross AJ. et al. Multi-analyte profiling in human carotid atherosclerosis uncovers pro-inflammatory macrophage programming in plaques. Thromb Haemost 2016; 115: 1064-1072.
48 Wang X, Sundquist K, Elf JL. et al. “Diagnostic potential of plasma microRNA signatures in patients with deep vein thrombosis”. Thromb Haemost 2016; 116: 328-336.
49 Morbiducci U, Kok AM, Kwak BR. et al. Atherosclerosis at arterial bifurcations: evidence for the role of haemodynamics and geometry. Thromb Haemost 2016; 115: 484-492.
50 van der Heiden K, Hoogendoorn A, Daemen MJ, Gijsen FJ. Animal models for plaque rupture: a biomechanical assessment. Thromb Haemost 2016; 115: 501-508.
51 Lehoux S, Jones EA. Shear stress, arterial identity and atherosclerosis. Thromb Haemost 2016; 115: 467-473.
52 Fischer K, Lassila R, Peyvandi F. et al. EUHASS participants. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015; 113: 968-975.
53 López-Fernández MF, Altisent Roca C, Álvarez-Román MT. et al. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thromb Haemost 2016; 115: 872-895.